# US 12,109,249 B2 · Compositions and methods for treating inflammation and cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,109,249 B2
- Document ID: US12109249B2
- Status: Granted
- Kind: B2
- Application number: 16/965,797
- Filed: 2019-01-29
- Published: 2021-02-11
- Granted: 2024-10-08
- Earliest claimed: 2018-01-30
- Assignees: University of Louisville Research Foundation, Inc.
- Applicants: University of Louisville Research Foundation, Inc.
- Inventors: Nejat Egilmez; Neal Bhutiani
- Web page: https://patentgrep.com/patent/US12109249B2

## CPC

- A61K 38/2066: {IL-10}
- A61K 38/208: {IL-12}
- A61P 35/00: Antineoplastic agents
- C07K 16/244: {Interleukins [IL]}
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Compositions and methods for the treatment of cancer and/or inflammatory diseases are provided. A combination of interleukin-10 (IL-10) and interleukin-12 (IL-12) is used to treat cancer and/or inflammatory diseases, and a combination of an anti-PD-1 antibody and an anti-IL-17 antibody is used to treat cancer.

## Claims

### Claim 1

A method of treating a cancer in a subject in need thereof, comprising
treating the subject with an anti-PD-1 antibody,
measuring a level of IL-17 produced by CD4+ T-cells in the subject,
identifying an increase in IL-17 produced by CD4+ T-cells, and
administering to the subject a combination of an anti-IL-17 antibody and an anti-PD-1 antibody,
wherein the cancer is colon cancer or lung cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cancer is not responsive to treatment with the anti-PD-1 antibody alone.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cancer is lung cancer.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cancer is colon cancer.

### Claim 5 (depends on 1)

The method of claim 1, wherein the combination of the anti-IL-17 antibody and the anti-PD-1 antibody is administered in a singular formulation.

### Claim 6 (depends on 1)

The method of claim 1, wherein the combination of the anti-IL-17 antibody and the anti-PD-1 antibody is administered in separate formulations.

### Claim 7 (depends on 1)

The method of claim 1, wherein the IL-17 measured in the measuring step is IL-17A.